In people with recently diagnosed type 2 diabetes and no prior cardiovascular disease, self-reported physical activity ...

Released Tuesday, the AAP's recommendations call for routine vaccination of children ages 6 months to 2 years, citing ...

For the first time in 30 years, the American Academy of Pediatrics is substantially diverging from U.S. government vaccine ...

A large trial in a primary care setting found daily emollient use to be safe, feasible, and effective in reducing atopic ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Pfizer Inc. (NYSE:PFE) discovers, develops, markets, and sells biopharmaceutical products in the U.S. and internationally. It ...

In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma ...

One of the highest yields you can get right now is from Pfizer (NYSE: PFE). The healthcare giant offers a yield of 6.8%, ...

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...